Macugen® is indicated for the treatment of neovascular (wet) age-related macular degeneration. This product is manufactured by Pfizer Pharmaceuticals and is administered once every six weeks by intravitreous injection.
Pfizer Pharmaceuticals recently notified healthcare professionals of important changes in the approved product labeling for Macugen®, including changes to the CONTRAINDICATIONS, PRECAUTIONS, ADVERSE EVENTS Post-Marketing, and DOSAGE and ADMINISTRATION sections.
Read the press release.
.jpg)
Comment Preview